



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

June 2019





# HIV/AIDS Drug Treatment Program

## Monthly Report

© 2019 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
608 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.806.8202  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.cfenet.ubc.ca](http://www.cfenet.ubc.ca)  
Email: [info@cfenet.ubc.ca](mailto:info@cfenet.ubc.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
in HIV/AIDS



This document is best viewed in colour.  
Drug definitions available in the back.



## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





## TABLE OF CONTENTS

### 1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

June 2019

N = 7384



Health Authority	Male	Female	All
FRASER	1432	423	1855
INTERIOR	412	98	510
NORTHERN	136	84	220
VANCOUVER COASTAL	3393	454	3847
VANCOUVER ISLAND	763	158	921
	<b>6136</b>	<b>1217</b>	<b>7353</b>
		<b>Unknown/not stated:</b>	<b>31</b>
		<b>Total:</b>	<b>7384</b>

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (June 2014 - June 2019)






### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (June 2014 - June 2019)






### 1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (June 2014 - June 2019)






### 1.5 BC-CfE Enrollment: New Antiretroviral Participants (June 2014 - June 2019)






### 1.6 Percent Distribution of Active Participants by CD4 Count (June 2014 - June 2019)






### 1.7 Percent Distribution of Inactive Participants by CD4 Count (June 2014 - June 2019)






### 1.8 Active and Inactive Participants (June 2014 - June 2019)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (June 2014 - June 2019)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (June 2014 - June 2019)






### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(June 2014 - June 2019)






### 1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (June 2014 - June 2019)






### 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(June 2014 - June 2019)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (June 2014 - June 2019)






### 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(June 2014 - June 2019)





### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (June 2014 - June 2019)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(June 2014 - June 2019)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes






1.18 Baseline CD4 for Antiretroviral First Starts  
(June 2014 - June 2019)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART  
(June 2014 - June 2019)**






### 1.20 Cumulative Resistance Testing Results by Resistance Category (June 2014 - June 2019)





### 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (June 2014 - June 2019)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2019  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	27	5	0	5	3	840	5	<40	3
1988	28	6	0	6	6	455	6	<40	3
1989	26	53	1	54	45	490	52	<40	3
1990	25	54	1	55	44	505	55	<40	3
1991	25	38	3	41	29	570	39	<40	3
1992	25	62	5	67	44	585	65	<40	3
1993	24	136	16	152	131	560	146	<40	3
1994	23	83	12	95	76	500	91	<40	3
1995	22	126	23	149	125	560	145	<40	3
1996	20	349	56	405	328	580	388	<40	3
1997	19	291	31	322	276	640	314	<40	3
1998	18	198	42	240	197	540	232	<40	3
1999	18	163	39	202	163	540	193	<40	3
2000	18	126	31	157	127	580	145	<40	3
2001	17	125	33	158	125	540	149	<40	3
2002	16	123	27	150	123	560	147	<40	3
2003	16	159	31	190	151	620	182	<40	3
2004	15	162	41	203	170	600	196	<40	3
2005	14	189	44	233	189	630	223	<40	3
2006	13	189	43	232	186	605	221	<40	3
2007	12	260	50	310	252	610	293	<40	3
2008	11	292	71	363	296	665	349	<40	3
2009	10	322	68	390	323	660	373	<40	3
2010	9	282	72	354	295	650	339	<40	3
2011	8	327	76	403	324	680	379	<40	3
2012	7	278	66	344	282	700	328	<40	3
2013	6	272	64	336	278	670	324	<40	3
2014	5	284	54	338	262	705	318	<40	3
2015	4	296	51	347	285	650	333	<40	3
2016	3	278	53	331	256	660	309	<40	3
2017	2	239	36	275	231	630	263	<40	3
2018	1	231	54	285	242	628	282	<40	3
2019	0	137	27	164	153	550	160	<40	3
<b>Total:</b>		<b>6135</b>	<b>1221</b>	<b>7356</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	7281	750	2385	<40	2109	610
FEB-2018	7245	763	1904	<40	1743	610
MAR-2018	7270	769	2050	<40	1831	617
APR-2018	7256	776	2080	<40	1842	620
MAY-2018	7274	773	2147	<40	1928	600
JUN-2018	7275	787	2003	<40	1786	610
JUL-2018	7285	785	2037	<40	1810	600
AUG-2018	7289	795	2092	<40	1873	620
SEP-2018	7244	795	2015	<40	1787	620
OCT-2018	7338	776	2170	<40	1944	610
NOV-2018	7342	781	2092	<40	1814	630
DEC-2018	7359	788	1747	<40	1534	620
JAN-2019	7398	792	2456	<40	2135	610
FEB-2019	7381	799	1853	<40	1569	620
MAR-2019	7423	790	2086	<40	1733	610
APR-2019	7383	793	2144	<40	1703	610
MAY-2019	7438	796	2128	<40	1657	620
JUN-2019	7384	806	1924	<40	1456	620

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	1428	3315	79	890	71	380
FEB-2018	1472	3112	79	1036	66	440
MAR-2018	1456	3198	75	59	70	485
APR-2018	1474	3163	73	459	63	497
MAY-2018	1462	3229	93	<40	82	455
JUN-2018	1472	3230	73	1080	70	440
JUL-2018	1472	3261	70	<40	55	570
AUG-2018	1501	3172	64	63	60	485
SEP-2018	1546	2985	88	220	82	410
OCT-2018	1473	3335	79	<50	69	350
NOV-2018	1484	3312	81	83	73	480
DEC-2018	1480	3345	57	355	46	495
JAN-2019	1470	3415	73	73	65	350
FEB-2019	1498	3331	75	108	66	590
MAR-2019	1461	3507	74	885	60	400
APR-2019	1495	3414	79	<50	68	490
MAY-2019	1444	3637	77	82	65	460
JUN-2019	1505	3421	80	<40	64	490

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2018	7242	1428	12	12	193	127	56	13217
FEB-2018	7211	1472	11	27	125	169	-31	13254
MAR-2018	7231	1456	17	21	158	138	20	13281
APR-2018	7223	1474	12	15	154	161	-8	13303
MAY-2018	7244	1462	9	12	174	153	21	13328
JUN-2018	7240	1472	13	16	152	156	-4	13350
JUL-2018	7242	1472	13	13	165	155	2	13376
AUG-2018	7254	1501	9	27	158	159	12	13415
SEP-2018	7208	1546	14	15	155	195	-46	13441
OCT-2018	7307	1473	8	19	218	126	99	13477
NOV-2018	7316	1484	5	9	172	164	9	13503
DEC-2018	7333	1480	11	19	152	142	17	13528
JAN-2019	7367	1470	14	20	191	160	34	13563
FEB-2019	7355	1498	7	16	161	179	-12	13592
MAR-2019	7384	1461	15	13	188	146	29	13612
APR-2019	7347	1495	9	16	150	176	-37	13640
MAY-2019	7411	1444	10	21	195	138	64	13682
JUN-2019	7356	1505	13	14	134	189	-55	13702

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2018	60	6718	448	55	<b>7281</b>	0.82%	92.27%	6.15%	0.76%	<b>100.00%</b>
FEB-2018	64	6672	450	59	<b>7245</b>	0.88%	92.09%	6.21%	0.81%	<b>100.00%</b>
MAR-2018	62	6699	453	56	<b>7270</b>	0.85%	92.15%	6.23%	0.77%	<b>100.00%</b>
APR-2018	62	6688	449	57	<b>7256</b>	0.85%	92.17%	6.19%	0.79%	<b>100.00%</b>
MAY-2018	69	6692	455	58	<b>7274</b>	0.95%	92.00%	6.26%	0.80%	<b>100.00%</b>
JUN-2018	62	6709	447	57	<b>7275</b>	0.85%	92.22%	6.14%	0.78%	<b>100.00%</b>
JUL-2018	53	6719	458	55	<b>7285</b>	0.73%	92.23%	6.29%	0.75%	<b>100.00%</b>
AUG-2018	54	6725	454	56	<b>7289</b>	0.74%	92.26%	6.23%	0.77%	<b>100.00%</b>
SEP-2018	53	6678	456	57	<b>7244</b>	0.73%	92.19%	6.29%	0.79%	<b>100.00%</b>
OCT-2018	53	6757	474	54	<b>7338</b>	0.72%	92.08%	6.46%	0.74%	<b>100.00%</b>
NOV-2018	53	6764	475	50	<b>7342</b>	0.72%	92.13%	6.47%	0.68%	<b>100.00%</b>
DEC-2018	52	6781	477	49	<b>7359</b>	0.71%	92.15%	6.48%	0.67%	<b>100.00%</b>
JAN-2019	54	6805	486	53	<b>7398</b>	0.73%	91.98%	6.57%	0.72%	<b>100.00%</b>
FEB-2019	52	6788	492	49	<b>7381</b>	0.70%	91.97%	6.67%	0.66%	<b>100.00%</b>
MAR-2019	59	6824	490	50	<b>7423</b>	0.79%	91.93%	6.60%	0.67%	<b>100.00%</b>
APR-2019	56	6789	490	48	<b>7383</b>	0.76%	91.95%	6.64%	0.65%	<b>100.00%</b>
MAY-2019	55	6846	492	45	<b>7438</b>	0.74%	92.04%	6.61%	0.61%	<b>100.00%</b>
JUN-2019	57	6796	483	48	<b>7384</b>	0.77%	92.04%	6.54%	0.65%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	10 36%	3314 47%	9 32%	3070 43%	1 4%	61 1%	0 0%	5 0%	0 0%	4 0%	2 7%	292 4%	16 57%	3628 51%
FEB-2018	13 35%	3315 47%	12 32%	3073 44%	0 0%	61 1%	0 0%	5 0%	0 0%	4 0%	0 0%	299 4%	25 68%	3578 51%
MAR-2018	10 37%	3334 47%	10 37%	3099 44%	0 0%	59 1%	0 0%	4 0%	0 0%	4 0%	0 0%	311 4%	17 63%	3564 50%
APR-2018	5 23%	3342 47%	5 23%	3111 44%	0 0%	55 1%	0 0%	3 0%	0 0%	4 0%	2 9%	333 5%	15 68%	3533 50%
MAY-2018	9 39%	3351 48%	8 35%	3125 44%	1 4%	57 1%	0 0%	5 0%	0 0%	4 0%	1 4%	351 5%	13 57%	3504 50%
JUN-2018	7 35%	3365 48%	7 35%	3142 45%	0 0%	53 1%	0 0%	5 0%	0 0%	3 0%	1 5%	379 5%	12 60%	3474 49%
JUL-2018	7 28%	3394 48%	7 28%	3172 45%	0 0%	51 1%	0 0%	5 0%	0 0%	3 0%	4 16%	398 6%	14 56%	3445 49%
AUG-2018	13 33%	3393 48%	14 36%	3181 45%	0 0%	50 1%	0 0%	4 0%	0 0%	3 0%	2 5%	415 6%	23 59%	3414 48%
SEP-2018	4 15%	3377 48%	3 12%	3162 45%	1 4%	47 1%	0 0%	4 0%	0 0%	2 0%	4 15%	446 6%	18 69%	3365 48%
OCT-2018	11 31%	3418 48%	9 26%	3205 45%	1 3%	49 1%	0 0%	3 0%	0 0%	2 0%	0 0%	479 7%	25 71%	3382 47%
NOV-2018	9 35%	3428 48%	8 31%	3214 45%	0 0%	47 1%	0 0%	4 0%	0 0%	2 0%	1 4%	491 7%	17 65%	3352 47%
DEC-2018	8 32%	3446 48%	8 32%	3233 45%	0 0%	45 1%	0 0%	4 0%	0 0%	1 0%	2 8%	504 7%	15 60%	3349 47%
JAN-2019	8 23%	3471 48%	7 20%	3258 45%	1 3%	45 1%	0 0%	4 0%	0 0%	1 0%	1 3%	519 7%	26 74%	3360 47%
FEB-2019	13 45%	3465 48%	12 41%	3264 45%	0 0%	44 1%	0 0%	1 0%	0 0%	1 0%	3 10%	542 8%	13 45%	3311 46%
MAR-2019	6 30%	3479 48%	6 30%	3282 45%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 10%	559 8%	12 60%	3314 46%
APR-2019	12 43%	3481 48%	12 43%	3289 46%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 7%	587 8%	14 50%	3259 45%
MAY-2019	14 34%	3512 49%	14 34%	3320 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	4 10%	594 8%	23 56%	3267 45%
JUN-2019	3 15%	3495 49%	3 15%	3307 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	2 10%	609 8%	15 75%	3205 45%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)**

	emtricitabine			
	Initial	%	All	%
JAN-2018	18	64%	3704	52%
FEB-2018	24	65%	3672	52%
MAR-2018	17	63%	3670	52%
APR-2018	17	77%	3655	52%
MAY-2018	14	61%	3650	52%
JUN-2018	13	65%	3651	52%
JUL-2018	18	72%	3648	52%
AUG-2018	25	64%	3647	52%
SEP-2018	22	85%	3625	51%
OCT-2018	24	69%	3683	52%
NOV-2018	17	65%	3668	51%
DEC-2018	17	68%	3670	51%
JAN-2019	27	77%	3699	51%
FEB-2019	16	55%	3680	51%
MAR-2019	14	70%	3710	51%
APR-2019	16	57%	3675	51%
MAY-2019	27	66%	3697	51%
JUN-2019	17	85%	3652	51%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	8 0%	3 30%	1313 45%	7 70%	1414 48%	0 0%	195 7%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
FEB-2018	0 0%	6 0%	0 0%	1255 44%	15 100%	1420 49%	0 0%	189 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAR-2018	0 0%	7 0%	1 9%	1243 43%	10 91%	1438 50%	0 0%	187 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
APR-2018	0 0%	6 0%	0 0%	1220 43%	11 100%	1435 50%	0 0%	180 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2018	0 0%	7 0%	0 0%	1204 42%	5 100%	1438 51%	0 0%	181 6%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JUN-2018	0 0%	7 0%	1 8%	1185 42%	11 92%	1428 51%	0 0%	175 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
JUL-2018	0 0%	7 0%	2 20%	1168 42%	7 70%	1438 52%	1 10%	168 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
AUG-2018	0 0%	7 0%	5 31%	1155 42%	11 69%	1423 52%	0 0%	166 6%	0 0%	1 0%	0 0%	1 0%	0 0%	8 0%
SEP-2018	0 0%	7 0%	1 14%	1132 42%	6 86%	1405 52%	0 0%	159 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
OCT-2018	0 0%	7 0%	3 17%	1121 41%	15 83%	1446 53%	0 0%	153 6%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
NOV-2018	0 0%	6 0%	1 14%	1116 41%	6 86%	1456 53%	0 0%	146 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
DEC-2018	0 0%	5 0%	1 11%	1106 41%	7 78%	1457 54%	1 11%	145 5%	0 0%	0 0%	0 0%	2 0%	0 0%	9 0%
JAN-2019	0 0%	6 0%	1 8%	1098 40%	11 92%	1478 54%	0 0%	140 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
FEB-2019	0 0%	5 0%	2 18%	1071 40%	9 82%	1475 55%	0 0%	138 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
MAR-2019	0 0%	5 0%	2 40%	1054 39%	3 60%	1487 55%	0 0%	133 5%	0 0%	1 0%	0 0%	1 0%	0 0%	7 0%
APR-2019	0 0%	5 0%	1 10%	1031 39%	7 70%	1480 56%	2 20%	133 5%	0 0%	2 0%	0 0%	1 0%	0 0%	7 0%
MAY-2019	0 0%	5 0%	1 8%	1034 39%	11 92%	1483 56%	0 0%	130 5%	0 0%	2 0%	0 0%	1 0%	0 0%	6 0%
JUN-2019	0 0%	5 0%	0 0%	1006 39%	9 100%	1472 57%	0 0%	120 5%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2018	0	0%	1	0%
FEB-2018	0	0%	1	0%
MAR-2018	0	0%	1	0%
APR-2018	0	0%	1	0%
MAY-2018	0	0%	1	0%
JUN-2018	0	0%	1	0%
JUL-2018	0	0%	1	0%
AUG-2018	0	0%	1	0%
SEP-2018	0	0%	1	0%
OCT-2018	0	0%	1	0%
NOV-2018	0	0%	1	0%
DEC-2018	0	0%	1	0%
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%
APR-2019	0	0%	1	0%
MAY-2019	0	0%	1	0%
JUN-2019	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	3 50%	778 37%	1 17%	262 12%	2 33%	757 36%	0 0%	302 14%
FEB-2018	3 75%	769 37%	0 0%	257 12%	0 0%	749 36%	1 25%	306 15%
MAR-2018	1 33%	757 37%	0 0%	250 12%	0 0%	736 36%	2 67%	311 15%
APR-2018	1 50%	745 37%	0 0%	245 12%	0 0%	731 36%	1 50%	318 16%
MAY-2018	4 67%	725 36%	1 17%	252 12%	0 0%	727 36%	1 17%	316 16%
JUN-2018	1 50%	721 36%	0 0%	248 12%	0 0%	724 36%	1 50%	313 16%
JUL-2018	3 60%	722 36%	0 0%	243 12%	0 0%	717 36%	2 40%	313 16%
AUG-2018	2 100%	714 36%	0 0%	238 12%	0 0%	716 36%	0 0%	308 16%
SEP-2018	6 100%	706 36%	0 0%	236 12%	0 0%	712 36%	0 0%	311 16%
OCT-2018	3 60%	696 36%	0 0%	234 12%	0 0%	710 36%	2 40%	323 16%
NOV-2018	8 80%	687 35%	0 0%	230 12%	0 0%	700 36%	2 20%	322 17%
DEC-2018	1 100%	684 36%	0 0%	225 12%	0 0%	696 36%	0 0%	319 17%
JAN-2019	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%
FEB-2019	2 67%	668 35%	1 33%	226 12%	0 0%	683 36%	0 0%	313 17%
MAR-2019	3 75%	661 35%	0 0%	224 12%	1 25%	681 36%	0 0%	322 17%
APR-2019	4 100%	646 35%	0 0%	223 12%	0 0%	678 36%	0 0%	320 17%
MAY-2019	5 100%	647 35%	0 0%	219 12%	0 0%	672 36%	0 0%	323 17%
JUN-2019	3 75%	633 35%	0 0%	211 12%	0 0%	664 36%	1 25%	319 17%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	0 0%	9 47%	2003 60%	8 42%	630 19%	0 0%	46 1%	2 11%	685 21%
FEB-2018	0 0%	0 0%	16 70%	2023 60%	6 26%	640 19%	0 0%	45 1%	1 4%	675 20%
MAR-2018	0 0%	0 0%	14 100%	2058 61%	0 0%	645 19%	0 0%	43 1%	0 0%	674 20%
APR-2018	0 0%	0 0%	8 67%	2102 61%	4 33%	653 19%	0 0%	44 1%	0 0%	681 20%
MAY-2018	0 0%	0 0%	13 65%	2136 61%	4 20%	664 19%	1 5%	42 1%	3 15%	675 19%
JUN-2018	0 0%	0 0%	8 73%	2168 62%	2 18%	672 19%	0 0%	42 1%	1 9%	676 19%
JUL-2018	0 0%	0 0%	7 58%	2202 62%	4 33%	674 19%	0 0%	42 1%	1 8%	675 19%
AUG-2018	0 0%	0 0%	23 79%	2252 62%	5 17%	675 19%	0 0%	42 1%	1 3%	671 19%
SEP-2018	0 0%	9 0%	5 36%	2261 62%	9 64%	689 19%	0 0%	41 1%	0 0%	655 18%
OCT-2018	0 0%	17 0%	13 76%	2318 63%	4 24%	708 19%	0 0%	40 1%	0 0%	658 18%
NOV-2018	0 0%	17 0%	11 100%	2344 63%	0 0%	704 19%	0 0%	38 1%	0 0%	650 17%
DEC-2018	0 0%	17 0%	13 76%	2367 63%	4 24%	720 19%	0 0%	39 1%	0 0%	652 17%
JAN-2019	0 0%	16 0%	15 75%	2430 63%	4 20%	730 19%	0 0%	39 1%	1 5%	651 17%
FEB-2019	0 0%	27 1%	16 73%	2438 63%	5 23%	727 19%	0 0%	40 1%	1 5%	653 17%
MAR-2019	0 0%	27 1%	8 62%	2488 64%	5 38%	747 19%	0 0%	38 1%	0 0%	647 17%
APR-2019	0 0%	27 1%	8 57%	2505 64%	3 21%	740 19%	0 0%	36 1%	3 21%	637 16%
MAY-2019	0 0%	27 1%	19 68%	2568 64%	6 21%	749 19%	0 0%	37 1%	3 11%	636 16%
JUN-2019	0 0%	27 1%	9 75%	2568 65%	3 25%	749 19%	0 0%	37 1%	0 0%	624 16%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2018	2004	27.52	1644	22.58	2592	35.60	117	1.61	55	0.76	869	11.94
FEB-2018	1961	27.07	1629	22.48	2610	36.02	116	1.60	59	0.81	870	12.01
MAR-2018	1974	27.15	1615	22.21	2644	36.37	113	1.55	56	0.77	868	11.94
APR-2018	1928	26.57	1596	22.00	2696	37.16	114	1.57	57	0.79	865	11.92
MAY-2018	1918	26.37	1575	21.65	2733	37.57	114	1.57	58	0.80	876	12.04
JUN-2018	1903	26.16	1563	21.48	2785	38.28	113	1.55	57	0.78	854	11.74
JUL-2018	1886	25.89	1566	21.50	2814	38.63	110	1.51	55	0.75	854	11.72
AUG-2018	1862	25.55	1549	21.25	2860	39.24	111	1.52	56	0.77	851	11.68
SEP-2018	1825	25.19	1532	21.15	2878	39.73	109	1.50	57	0.79	843	11.64
OCT-2018	1849	25.20	1529	20.84	2946	40.15	104	1.42	54	0.74	856	11.67
NOV-2018	1842	25.09	1522	20.73	2967	40.41	106	1.44	50	0.68	855	11.65
DEC-2018	1835	24.94	1510	20.52	3006	40.85	104	1.41	49	0.67	855	11.62
JAN-2019	1833	24.78	1481	20.02	3063	41.40	100	1.35	53	0.72	868	11.73
FEB-2019	1805	24.45	1479	20.04	3081	41.74	99	1.34	49	0.66	868	11.76
MAR-2019	1795	24.18	1474	19.86	3135	42.23	99	1.33	50	0.67	870	11.72
APR-2019	1765	23.91	1461	19.79	3151	42.68	101	1.37	48	0.65	857	11.61
MAY-2019	1776	23.88	1449	19.48	3213	43.20	97	1.30	45	0.61	858	11.54
JUN-2019	1748	23.67	1439	19.49	3210	43.47	95	1.29	48	0.65	844	11.43

**Definitions:**

n is number of participants on the specified regimen class in the specified month  
 % is ratio of n and total number of participants on ART in the specified month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2018	12	1	1	0	4	4	470
FEB-2018	27	3	2	2	6	13	485
MAR-2018	21	4	1	5	4	6	325
APR-2018	15	0	0	5	3	5	480
MAY-2018	12	1	0	4	3	2	370
JUN-2018	16	3	5	1	1	6	237
JUL-2018	13	4	1	3	4	1	284
AUG-2018	27	2	2	6	4	13	450
SEP-2018	15	2	3	1	3	5	405
OCT-2018	19	0	1	2	5	10	525
NOV-2018	9	2	2	2	0	2	185
DEC-2018	19	2	0	5	5	7	380
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	13	1	2	1	5	4	450
APR-2019	16	3	3	1	3	4	368
MAY-2019	21	1	0	6	8	4	440
JUN-2019	14	2	1	1	2	6	470

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start





**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2018	11957	3653
FEB-2018	11987	3668
MAR-2018	12015	3698
APR-2018	12047	3728
MAY-2018	12082	3753
JUN-2018	12094	3756
JUL-2018	12120	3780
AUG-2018	12134	3775
SEP-2018	12157	3796
OCT-2018	12176	3796
NOV-2018	12213	3815
DEC-2018	12217	3810
JAN-2019	12257	3835
FEB-2019	12264	3833
MAR-2019	12294	3863
APR-2019	12322	3887
MAY-2019	12340	3889
JUN-2019	12341	3895

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved  
**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants  
June 2019

N = 7384

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2019

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2019

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2019

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2019

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2019

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





**4.1 Distribution of Participants in BC-CfE Registries by Age and Gender  
INTERIOR Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	6	6	*
	35-49	11	13	*
	50+	26	37	*
	<b>Total HSDA:</b>	<b>43</b>	<b>56</b>	<b>28</b>
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>73</b>	<b>97</b>	<b>53</b>	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>368</b>	<b>493</b>	<b>283</b>	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	12
	35-49	*	*	45
	50+	*	*	89
<b>Total HSDA:</b>	<b>192</b>	<b>257</b>	<b>146</b>	
<b>Total HA:</b>		<b>676</b>	<b>903</b>	<b>510</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	*
	20-34	64	65	*
	35-49	178	199	*
	50+	429	634	*
<b>Total HA:</b>		<b>676</b>	<b>903</b>	<b>510</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	540	724	412
Female	136	179	98

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	510	55	620	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration  
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	11
	5 years or more	11	6
	<5 years	14	11
	<b>Total HSDA:</b>	<b>43</b>	<b>28</b>
KOOTENAY BOUNDARY	10 years or more	44	30
	5 years or more	15	11
	<5 years	14	12
	<b>Total HSDA:</b>	<b>73</b>	<b>53</b>
OKANAGAN	10 years or more	229	171
	5 years or more	66	52
	<5 years	73	60
	<b>Total HSDA:</b>	<b>368</b>	<b>283</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	107	76
	5 years or more	39	34
	<5 years	46	36
	<b>Total HSDA:</b>	<b>192</b>	<b>146</b>
<b>Total HA:</b>		<b>676</b>	<b>510</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	398	288
	5 years or more	131	103
	<5 years	147	119
<b>Total HA:</b>		<b>676</b>	<b>510</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	41	59	12	25
KOOTENAY BOUNDARY	69	121	20	44
OKANAGAN	213	914	58	285
THOMPSON/CARIBOO/SHUSWAP	132	503	39	134
<b>Total:</b>	<b>455</b>	<b>1597</b>	<b>129</b>	<b>488</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
<b>Total:</b>	<b>100</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	7
	20-34	28	30	20
	35-49	107	117	80
	50+	228	302	180
	<b>Total HSDA:</b>		<b>370</b>	<b>456</b>
FRASER NORTH	0-19	10	10	*
	20-34	107	108	*
	35-49	359	391	*
	50+	535	857	*
	<b>Total HSDA:</b>		<b>1011</b>	<b>1366</b>
FRASER SOUTH	0-19	7	7	*
	20-34	117	119	*
	35-49	337	383	*
	50+	523	774	*
	<b>Total HSDA:</b>		<b>984</b>	<b>1283</b>
<b>Total HA:</b>		<b>2365</b>	<b>3105</b>	<b>1855</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	24	24	13
	20-34	252	257	175
	35-49	803	891	629
	50+	1286	1933	1038
<b>Total HA:</b>		<b>2365</b>	<b>3105</b>	<b>1855</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1796	2381	1432
Female	569	724	423

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1855	51	626	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration  
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	209	162
	5 years or more	82	64
	<5 years	79	61
	<b>Total HSDA:</b>	<b>370</b>	<b>287</b>
FRASER NORTH	10 years or more	551	392
	5 years or more	246	198
	<5 years	214	181
	<b>Total HSDA:</b>	<b>1011</b>	<b>771</b>
FRASER SOUTH	10 years or more	531	424
	5 years or more	223	178
	<5 years	230	195
	<b>Total HSDA:</b>	<b>984</b>	<b>797</b>
<b>Total HA:</b>		<b>2365</b>	<b>1855</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	1291	978
5 years or more	551	440
<5 years	523	437
<b>Total HA:</b>	<b>2365</b>	<b>1855</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





#### 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	140	490	32	67
FRASER NORTH	248	1550	48	237
FRASER SOUTH	212	1444	45	458
<b>Total:</b>	<b>600</b>	<b>3484</b>	<b>125</b>	<b>762</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	197
FRASER NORTH	641
FRASER SOUTH	493
<b>Total:</b>	<b>1331</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	20
	35-49	*	*	59
	50+	*	*	200
	<b>Total HSDA:</b>		<b>333</b>	<b>480</b>
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>170</b>	<b>219</b>
VANCOUVER	0-19	35	35	7
	20-34	437	451	320
	35-49	1394	1576	1013
	50+	2784	4737	2093
	<b>Total HSDA:</b>	<b>4650</b>	<b>6799</b>	<b>3433</b>
<b>Total HA:</b>		<b>5153</b>	<b>7498</b>	<b>3847</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	38	38	8
	20-34	487	502	357
	35-49	1515	1709	1107
	50+	3113	5249	2375
<b>Total HA:</b>		<b>5153</b>	<b>7498</b>	<b>3847</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4543	6582	3393
Female	608	914	454

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3847	53	630	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	184	148
	5 years or more	83	70
	<5 years	66	61
	<b>Total HSDA:</b>	<b>333</b>	<b>279</b>
RICHMOND	10 years or more	97	71
	5 years or more	37	32
	<5 years	36	32
	<b>Total HSDA:</b>	<b>170</b>	<b>135</b>
VANCOUVER	10 years or more	2690	1919
	5 years or more	1186	867
	<5 years	774	647
	Never on ART	0	0
	<b>Total HSDA:</b>	<b>4650</b>	<b>3433</b>
<b>Total HA:</b>	<b>5153</b>	<b>3847</b>	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2971	2138
5 years or more	1306	969
<5 years	876	740
Never on ART	0	0
<b>Total HA:</b>	<b>5153</b>	<b>3847</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	168	487	52	172
RICHMOND	43	285	11	93
VANCOUVER	592	10713	196	5314
<b>Total:</b>	<b>803</b>	<b>11485</b>	<b>259</b>	<b>5579</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
<b>Total:</b>	<b>107</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	0
	20-34	*	*	20
	35-49	*	*	67
	50+	*	*	170
	<b>Total HSDA:</b>		<b>317</b>	<b>448</b>
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>124</b>	<b>166</b>
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>724</b>	<b>1028</b>
<b>Total HA:</b>		<b>1165</b>	<b>1642</b>	<b>921</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	*
	20-34	102	109	*
	35-49	310	361	*
	50+	746	1165	*
<b>Total HA:</b>		<b>1165</b>	<b>1642</b>	<b>921</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	958	1350	763
Female	207	292	158

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	921	54	540	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	170	142
	5 years or more	71	56
	<5 years	76	59
	<b>Total HSDA:</b>	<b>317</b>	<b>257</b>
NORTH VANCOUVER ISLAND	10 years or more	69	57
	5 years or more	31	23
	<5 years	24	22
	<b>Total HSDA:</b>	<b>124</b>	<b>102</b>
SOUTH VANCOUVER ISLAND	10 years or more	418	303
	5 years or more	156	132
	<5 years	150	127
	<b>Total HSDA:</b>	<b>724</b>	<b>562</b>
<b>Total HA:</b>		<b>1165</b>	<b>921</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	657	502
	5 years or more	258	211
	<5 years	250	208
<b>Total HA:</b>		<b>1165</b>	<b>921</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	191	851	72	197
NORTH VANCOUVER ISLAND	135	263	46	78
SOUTH VANCOUVER ISLAND	208	1763	42	549
<b>Total:</b>	<b>534</b>	<b>2877</b>	<b>160</b>	<b>824</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	50
NORTH VANCOUVER ISLAND	37
SOUTH VANCOUVER ISLAND	108
<b>Total:</b>	<b>195</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





### 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>40</b>	<b>48</b>
NORTH WEST	0-19	*	*	0
	20-34	*	*	8
	35-49	*	*	15
	50+	*	*	33
	<b>Total HSDA:</b>		<b>71</b>	<b>109</b>
NORTHERN INTERIOR	0-19	5	5	*
	20-34	20	22	*
	35-49	73	90	*
	50+	87	146	*
	<b>Total HSDA:</b>		<b>185</b>	<b>263</b>
<b>Total HA:</b>		<b>296</b>	<b>420</b>	<b>220</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	*
	20-34	34	37	*
	35-49	111	148	*
	50+	144	228	*
<b>Total HA:</b>		<b>296</b>	<b>420</b>	<b>220</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	179	259	136
Female	117	161	84

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	220	50	560	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	20	*
	5 years or more	13	*
	<5 years	7	*
	<b>Total HSDA:</b>	<b>40</b>	<b>21</b>
NORTH WEST	10 years or more	33	24
	5 years or more	24	20
	<5 years	14	12
	<b>Total HSDA:</b>	<b>71</b>	<b>56</b>
NORTHERN INTERIOR	10 years or more	74	53
	5 years or more	58	51
	<5 years	53	39
	<b>Total HSDA:</b>	<b>185</b>	<b>143</b>
<b>Total HA:</b>		<b>296</b>	<b>220</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	127	87
	5 years or more	95	79
	<5 years	74	54
<b>Total HA:</b>		<b>296</b>	<b>220</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	38	62	6	7
NORTH WEST	71	161	12	30
NORTHERN INTERIOR	105	455	15	177
<b>Total:</b>	<b>214</b>	<b>678</b>	<b>33</b>	<b>214</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	21
NORTHERN INTERIOR	18
<b>Total:</b>	<b>45</b>

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





### 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	*
	KOOTENAY BOUNDARY	6	9	*
	OKANAGAN	21	37	*
	THOMPSON/CARIBOO/SHUSWAP	25	44	*
	<b>Total HA:</b>	<b>58</b>	<b>100</b>	<b>42</b>
FRASER	FRASER EAST	44	54	36
	FRASER NORTH	55	91	44
	FRASER SOUTH	70	103	51
	<b>Total HA:</b>	<b>169</b>	<b>248</b>	<b>131</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	48	24
	RICHMOND	12	17	10
	VANCOUVER	494	855	395
	<b>Total HA:</b>	<b>531</b>	<b>920</b>	<b>429</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	49	77	39
	NORTH VANCOUVER ISLAND	17	26	16
	SOUTH VANCOUVER ISLAND	36	79	28
	<b>Total HA:</b>	<b>102</b>	<b>182</b>	<b>83</b>
NORTHERN	NORTH EAST	10	12	6
	NORTH WEST	31	60	24
	NORTHERN INTERIOR	67	104	55
	<b>Total HA:</b>	<b>108</b>	<b>176</b>	<b>85</b>
<b>Total:</b>		<b>968</b>	<b>1626</b>	<b>770</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	602	1033	477
Female	366	593	293

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	770	51	480	35

\* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir (Ziagen, ABC):** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Amphotericin B (Fungilin):** a drug used for treatment of candidiasis and other fungal infections.

**Amprenavir (Agenerase, APV):** a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz, ATV):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla (ATP):** the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Bictegravir:** an INTEGRASE INHIBITOR from Gilead Sciences.

**Boosted PI:** a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Cobicistat:** a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

**Combination Therapy:** initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Combivir (CBV):** the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

**Complera (CPL):** the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





**Descovy (DSC):** the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

**Didanosine (Videx, DDI):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (Tivicay, DTG):** an INTEGRASE INHIBITOR from ViiV Healthcare.

**Efavirenz (Sustiva, Auro efavirenz, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

**Emtricitabine (FTC):** a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (Intence, ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Genvoya (GNV):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa (KIV):** the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

**Lamivudine (3TC):** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra, LPV/r):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

**Maraviroc (Celsentri, MVC):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by





blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept, NFV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**NRTI:** see NUCLEOSIDE ANALOG.

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Octreotide Acetate (Sandostatin):** a drug used to treat chronic refractory diarrhea.

**Odefsey (ODF):** the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prezcobix (PZC):** the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (RGV, Isentress):** an INTEGRASE INHIBITOR from Merck.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant, RPV):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

**Saquinavir (Invirase, SQV):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit, d4T):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

**Tenofovir alafenamide (Tenofovir AF, TAF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

**Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Triumeq (TRQ):** the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

**Trizivir (TRZ):** the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

**Truvada (TRU):** the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

